ClinicalTrials.gg
CompletedNCT05902728Updated Apr 5, 2024

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

A Phase 1 interventional study of HLX208 and HLX208 in NSCLC, sponsored by Shanghai Henlius Biotech. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is divided into Part I and Part II. Part I is the food effect study. A total of 20 healthy subjects, regardless of gender, will be enrolled in a randomized, open-label, crossover design.

Part II is the drug-drug interaction study, an open-label and sequential design. 32 healthy subjects are planned to be enrolled and divided into group A and group B. Group A is to evaluate the influence of itraconazole as CYP3A4 strong inhibitory on HLX208. Group B was to evaluate the effect of rifampicin as a strong inducer of CYP3A4 on HLX208.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the before the trial, and fully understand the content, process and possible adverse reactions of the trial. Must be able to communicate with the investigator, understand and comply with all study requirements;
  2. Male or female subjects aged 18 to 45 (including 18 and 45);
  3. Weigh at least 50 kg (for male) and 45 kg (for female), respectively, and have a (BMI) ≥ 19 and ≤26 kg/m2. BMI = weight (kg)/[height (m)]2;

Exclusion criteria

Exclusion Criteria:

  1. Known history of drug or food allergy;
  2. Those who have a positive urine drug screen or have a history of drug abuse;
  3. Excessive smoking (≥ 5 cigarettes/day);
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HLX208 in the fast state

    HLX208 900mg in the fast state

    Drug: HLX208

  • Experimental
    HLX208 in the fed state

    HLX208 900mg in the fed state

    Drug: HLX208

  • Experimental
    HLX208 + Itraconazole group

    HLX208 + Itraconazole group

    Drug: HLX208 · Drug: Itraconazole 200 mg

  • Experimental
    HLX208 + rifampicin group

    HLX208 + rifampicin group

    Drug: HLX208 · Drug: Rifampicin

Interventions

  • DrugHLX208

    Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ,then receive treatment HLX208 900 mg in the fed state

  • DrugHLX208

    Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ,then receive treatment HLX208 900 mg in the fast state.

  • DrugHLX208

    450 mg

  • DrugHLX208

    900 mg

  • DrugItraconazole 200 mg

    200 mg

  • DrugRifampicin

    600mg

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameter Cmax of HLX208

    Cmax of HLX208

    Time frame: up to 48 hours

  2. Pharmacokinetics parameter AUC0-t of HLX208

    AUC0-t of HLX208

    Time frame: up to 48 hours

  3. Pharmacokinetics parameter AUC0-inf of HLX208

    AUC0-inf of HLX208

    Time frame: up to 48 hours

Secondary outcomes

  1. other pharmacokinetics parameter Tmax of HLX208

    Tmax of HLX208

    Time frame: up to 48 hours

  2. other pharmacokinetics parameter Tlag of HLX208

    Tlag of HLX208

    Time frame: up to 48 hours

  3. other pharmacokinetics parameter t1/2 of HLX208

    t1/2 of HLX208

    Time frame: up to 48 hours

  4. other pharmacokinetics parameter CL/F of HLX208

    CL/F of HLX208

    Time frame: up to 48 hours

  5. other pharmacokinetics parameter Vd/F of HLX208

    Vd/F of HLX208

    Time frame: up to 48 hours

  6. other pharmacokinetics parameter MRT of HLX208

    MRT of HLX208

    Time frame: up to 48 hours

  7. other pharmacokinetics parameter %AUCex of HLX208

    %AUCex of HLX208

    Time frame: up to 48 hours

  8. The incidence and severity of adverse events/serious adverse events

    Occurrence of Serious Adverse Event (SAE), Adverse Event (AE)

    Time frame: up to 17 days after the last dose

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Dec 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 15, 2023
StartActual
Jul 4, 2023
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05902728
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jul 4, 2023
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Last update
Apr 5, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion